Advertisement

Reactions Weekly

, Volume 1770, Issue 1, pp 313–313 | Cite as

Nivolumab/pembrolizumab

Various toxicities: 16 case reports
Case report

Reference

  1. Swami U, et al. Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. Journal of Oncology 2019: 25 Jul 2019. Available from: URL: http://doi.org/10.1155/2019/1856594 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations